Miraculins Announces Private Placement Offering
(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 04/10/15 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces a non-brokered private placement offering (the "Offering") of up to 2,500,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of up to $250,000. Each Unit will be comprised of one common share of the Company (a "Share") and one Share purchase warrant. Each whole warrant (a "Warrant") will entitle the holder to purchase one Share at a price of $0.15 per Share for a period of 24 months from the date the Warrant is issued.
Certain persons may assist the Company by introducing potential subscribers for the Offering and, subject to compliance with applicable legislation, will be entitled to receive a finder''s fee, payable in cash and share purchase warrants, as permitted by law.
The net proceeds of the Offering will be used for general corporate purposes.
The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
204-453-1546 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2015 - 17:00 Uhr
Sprache: Deutsch
News-ID 1350555
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WINNIPEG, MANITOBA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Miraculins Announces Private Placement Offering
"
steht unter der journalistisch-redaktionellen Verantwortung von
Miraculins Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
